Table 1 Demographics and clinical data.

From: Salivary cortisol is associated with cognitive changes in patients with fibromyalgia

 

Controls (n = 48)

FM (n = 44)

P

Female

38 (79%)

40 (91%)

0.117

Age (year)

50.8 ± 7.2

50.7 ± 6.5

0.969

Education (year)

15.3 ± 2.7

13.9 ± 2.2

0.002

Disease duration (year)

3.9 ± 1.2

Average pain intensity

5.9 ± 2.4

TTP

4.7 ± 4.2

14.4 ± 3.0

 < 0.001

TTS

5.9 ± 6.1

26.5 ± 9.3

 < 0.001

WPI

1.4 ± 2.1

10.3 ± 4.1

 < 0.001

SSS

2.6 ± 2.0

8.0 ± 2.1

 < 0.001

Fatigue = 0

22 (50%)

2 (5%)

 < 0.001

Fatigue = 1

18 (41%)

10 (24%)

 

Fatigue = 2

4 (9%)

14 (33%)

 

Fatigue = 3

0 (0%)

16 (38%)

 

Cognitive symptoms = 0

20 (42%)

3 (7%)

 < 0.001

Cognitive symptoms = 1

21 (48%)

9 (21%)

 

Cognitive symptoms = 2

3 (7%)

21 (50%)

 

Cognitive symptoms = 3

0 (0%)

9 (21%)

 

Unrefreshed sleep = 0

19 (43%)

0 (0%)

 < 0.001

Unrefreshed sleep = 1

22 (50%)

5 (12%)

 

Unrefreshed sleep = 2

3 (7%)

21 (50%)

 

Unrefreshed sleep = 3

0 (0%)

16 (38%)

 

Headache = 1

16 (36%)

38 (91%)

 < 0.001

Abdominal pain = 1

7 (16%)

14 (33%)

0.060

Depression = 1

6 (14%)

25 (60%)

 < 0.001

BDI−I

5.2 ± 4.8

15.7 ± 9.9

 < 0.001

FIQR

6.6 ± 8.8

50.9 ± 21.7

 < 0.001

  1. Data are mean ± SD or number (%).
  2. FM fibromyalgia, TTP total tender points, TTS total tender point score, WPI widespread pain index, SSS symptom severe score, BDI–I Beck's Depression Inventory version 1, FIQR Revised fibromyalgia impact questionnaire.